刘灿, 贺宏吉, 苏文君, 黄佳敏, 董雪, 沈琪, 王梅. 黄体酮透皮贴剂和微针组合制剂的处方工艺和体外性质研究J. 药学学报, 2025, 60(3): 809-816. DOI: 10.16438/j.0513-4870.2024-0933
引用本文: 刘灿, 贺宏吉, 苏文君, 黄佳敏, 董雪, 沈琪, 王梅. 黄体酮透皮贴剂和微针组合制剂的处方工艺和体外性质研究J. 药学学报, 2025, 60(3): 809-816. DOI: 10.16438/j.0513-4870.2024-0933
LIU Can, HE Hong-ji, SU Wen-jun, HUANG Jia-min, DONG Xue, SHEN Qi, WANG Mei. Prescription process and in vitro study of transdermal patch and microneedle combination formulation of progesteroneJ. Acta Pharmaceutica Sinica, 2025, 60(3): 809-816. DOI: 10.16438/j.0513-4870.2024-0933
Citation: LIU Can, HE Hong-ji, SU Wen-jun, HUANG Jia-min, DONG Xue, SHEN Qi, WANG Mei. Prescription process and in vitro study of transdermal patch and microneedle combination formulation of progesteroneJ. Acta Pharmaceutica Sinica, 2025, 60(3): 809-816. DOI: 10.16438/j.0513-4870.2024-0933

黄体酮透皮贴剂和微针组合制剂的处方工艺和体外性质研究

Prescription process and in vitro study of transdermal patch and microneedle combination formulation of progesterone

  • 摘要: 本文旨在制备黄体酮压敏胶贴剂与微针组合制剂, 优化处方, 并考察其药物释放量。采用HPLC检测制剂中黄体酮含量, 通过单因素实验和正交实验, 以感官评价、黏附性、累积释放量、累积渗透量等为评价指标, 优选出贴剂最佳处方, 并用3D打印方法制备3种不同针高的微针, 将贴剂与微针组合测定其累积渗透量, 并与单纯贴剂进行对比。正交实验结果表明, 贴剂最优处方为Duro-Tak 87-2677压敏胶(87.5%)、柠檬酸三丁酯(2%)、肉豆蔻酸异丙酯(5%)、二丁基羟基甲苯(0.5%), 黄体酮含量(5%)。工艺验证结果表明, 按照优化处方制备的贴剂成形性、黏附性良好。在经皮渗透试验中, 24 h时空白组的累积渗透量为52.35 ± 7.88 μg·cm-2, 处方贴剂的累积渗透量为200.17 ± 6.15 μg·cm-2, 与500、750、1 000 μm微针组合贴剂的累积渗透量分别为226.01 ± 7.46、278.78 ± 6.59、422.95 ± 16.81 μg·cm-2。动物实验经新疆医科大学实验动物伦理委员会批准(伦理批号: IACUC-20220725-8)。通过单因素实验和正交实验, 筛选出最优贴剂处方, 且贴剂与微针组合制剂的透皮渗透效果比单用更好, 能有效增加了药物体外经皮渗透。以上研究为黄体酮透皮贴剂的应用提供了理论依据。

     

    Abstract: To prepare a progesterone pressure-sensitive gel patch combined with a microneedle to enhance drug release, HPLC was used to determine the preparation's progesterone content. One-way and orthogonal experiments were used to optimize the patch's prescription. Adhesion, sensory evaluation, cumulative release, and cumulative penetration were used as evaluation indices. Three microneedles with varying needle heights were made using 3D printing, and the cumulative penetration of the patch and microneedles was calculated and compared with the patch alone. The orthogonal experiments showed that the optimal prescription for the patches was Duro-Tak 87-2677 pressure-sensitive adhesive (87.5%), tributyl citrate (2%), isopropyl myristate (5%), dibutylated hydroxytoluene (0.5%), and drug (5%). The patches were prepared according to the optimized prescription, resulting in good patch formability and adhesion. In the transdermal penetration test, the cumulative penetration of the patch was 52.35 ± 7.88 μg·cm-2 at 24 h, and the cumulative penetration of the patch in combination with 500, 750, and 1 000 μm microneedles was 226.01 ± 7.46, 278.78 ± 6.59, 422.95 ± 16.81 μg·cm-2, respectively. The experiment was approved by the Experimental Animal Ethics Committee of Xinjiang Medical University (IACUC-20220725-8). The optimal patch prescription was screened through one-way and orthogonal experiments, and the transdermal penetration effect of patch and microneedle combination preparation was better than that of single use, which can effectively increase the in vitro transdermal penetration of the drug, and the above study provides a theoretical basis for the application of transdermal patches of progesterone.

     

/

返回文章
返回